|View printer-friendly version|
Goldman Sachs37th Annual Global Healthcare Conference at 10:00 a.m. PDT( 1:00 p.m. EDT), Wednesday, June 8, 2016in Rancho Palos Verdes, Calif.
Jefferies2016 Healthcare Conference at 12:30 p.m. EDT, Friday, June 10, 2016in New York City
Live, listen-only webcasts of the presentations will be accessible on the Events and Presentations page within the Investors and Media section of the
SMA is a severe neuromuscular disease characterized by the loss of motor neurons leading to progressive muscle weakness and paralysis. SMA is caused by a genetic defect in the SMN1 gene that codes SMN, a protein necessary for survival of motor neurons. The incidence of SMA is approximately one in 10,000 live births.
The most severe form of SMA is Type 1, a lethal genetic disorder characterized by motor neuron loss and associated muscle deterioration, which results in mortality or the need for permanent ventilation support before the age of two for greater than 90 percent of patients. SMA Type 1 is the leading genetic cause of infant mortality.
AVXS-101 is a proprietary gene therapy candidate of a one-time treatment for SMA Type 1 and is the only clinical-stage gene therapy in development for SMA. AVXS-101 is designed to address the monogenetic root cause of SMA and prevent further muscle degeneration by addressing the defective and/or loss of the primary SMN gene. AVXS-101 also targets motor neurons providing rapid onset of effect, and crosses the blood brain barrier allowing an IV dosing route and effective targeting of both central and systemic features.
Lauren Barbiero W2O Group646-564-2156 email@example.com Investor Inquiries: Jim Goff AveXis, Inc.650-862-4134 firstname.lastname@example.org